Baseline and Safety Data From Phase 2 Trial of Paxlovid to Treat Long COVID

Demystifying Long COVID International Conference 2023

Metformin Cuts Long COVID Risk 41% in Placebo-Controlled COVID-OUT Trial

Demystifying Long COVID International Conference 2023

Immune Responses Rebound to Normal in Long COVID Group But One Third “Still Very Ill”

Demystifying Long COVID International Conference 2023

Reports From France and UK Confirm Frequent Intransigence of Long COVID

Demystifying Long COVID International Conference 2023

Higher Vascular Markers in Neuropsychiatric Long COVID Point to Atherosclerosis Risk

Demystifying Long COVID International Conference 2023

Employment Type and Fear of Lost Income Tied to Persistent COVID Symptoms

Demystifying Long COVID International Conference 2023

Transcriptomics Sort Out Possible Markers and Mechanisms of Long COVID

Demystifying Long COVID International Conference 2023

Defining the syndrome, and clusters of symptoms: RECOVER Adult Cohort

Demystifying Long COVID International Conference 2023

SARS-CoV-2 antibody seroprevalence in previously undiagnosed persons in Tbilisi, Georgia: Results of three repeated serosurveys

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Rate of HCV reinfection among people living with HCV following successful DAA therapy in Tbilisi, Georgia

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

COVID-19 Challenges and Scale-up in Access to Community-based HCV Treatment for HIV/HCV Co-infected PWIDs in Ukraine

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Dynamics and peculiarities of AIDS mortality in Minsk, Belarus

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

“Evaluate potential impact of COVID-19 pandemic on HIV testing and care national program in the republic of Georgia”

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Effect of remdesivir on mortality in patients with COVID-19: A retrospective cohort study

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Integrating viral hepatitis and PrEP services through KP-led clinics in Vietnam: An opportunity to achieve dual elimination of HIV and viral hepatitis by 2030

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Prevalence of undiagnosed HBV infection in patients with COVID-19

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Obstetric complications in HIV-positive pregnant women, depending on the level of HIV RNA and CD4 count

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Post-discharge mortality among hospitalized HIV positive persons

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Outcomes of HIV pre-exposure prophylaxis (PrEP) program in Georgia for the reporting period from October 2017 to June 2021

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Surveillance of SARS-CoV-2 among employees of front-line healthcare facility in Tbilisi Georgia

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Incidence and residual risk of HCV in Lithuanian blood donors from 2004 to 2018: call for screening improvement in a general population

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Prevalence of hyperglycemia and its impact on mortality among HIV patients in Georgia

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Assessment of HCV screening and linkage to care modalities within the Georgia’s national Hepatitis C elimination program and designing the most optimal models for reaching the elimination targets

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Molecular epidemiology of Hepatitis C virus isolated from patients with newly diagnosed HCV infection in 2017-2021

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021